HK1210031A1 - Therapeutic agent or prophylactic agent for dementia - Google Patents

Therapeutic agent or prophylactic agent for dementia

Info

Publication number: HK1210031A1
Authority: HK; Hong Kong
Prior art keywords: agent; dementia; prophylactic; therapeutic agent; therapeutic
Prior art date: 2012-05-31

Application number

HK15110820.8A

Other languages

English (en)

Chinese (zh)

Inventor

森启

富山貴美

松本洋

江口廣志

九里裕

Original Assignee

Univ Osaka City

Teijin Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-31

Filing date

2015-11-03

Publication date

2016-04-15

2015-11-03 Application filed by Univ Osaka City, Teijin Pharma Ltd filed Critical Univ Osaka City

2016-04-15 Publication of HK1210031A1 publication Critical patent/HK1210031A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

HK15110820.8A 2012-05-31 2015-11-03 Therapeutic agent or prophylactic agent for dementia HK1210031A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2012124336		2012-05-31
PCT/JP2013/065090 WO2013180238A1 (ja)	2012-05-31	2013-05-30	認知症治療剤又は予防剤

Publications (1)

Publication Number	Publication Date
HK1210031A1 true HK1210031A1 (en)	2016-04-15

Family

ID=49673425

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15110820.8A HK1210031A1 (en)	2012-05-31	2015-11-03	Therapeutic agent or prophylactic agent for dementia

Country Status (31)

Country	Link
US (3)	US20150183854A1 (es)
EP (2)	EP2857039B1 (es)
JP (3)	JP5971659B2 (es)
KR (2)	KR102208283B1 (es)
CN (1)	CN104602708B (es)
AR (1)	AR091218A1 (es)
AU (2)	AU2013268364B2 (es)
BR (1)	BR112014029566A2 (es)
CA (1)	CA2875205C (es)
CY (1)	CY1122530T1 (es)
DK (1)	DK2857039T3 (es)
ES (2)	ES2973070T3 (es)
HK (1)	HK1210031A1 (es)
HR (1)	HRP20192267T1 (es)
HU (1)	HUE046919T2 (es)
IL (1)	IL235899B (es)
LT (1)	LT2857039T (es)
ME (1)	ME03587B (es)
MX (1)	MX361128B (es)
MY (1)	MY172458A (es)
NZ (1)	NZ630536A (es)
PH (1)	PH12014502669B1 (es)
PL (1)	PL2857039T3 (es)
PT (1)	PT2857039T (es)
RS (1)	RS59802B1 (es)
RU (1)	RU2657438C2 (es)
SG (2)	SG10201805410XA (es)
SI (1)	SI2857039T1 (es)
TW (2)	TWI777183B (es)
WO (1)	WO2013180238A1 (es)
ZA (1)	ZA201409186B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2670434B1 (en)	2011-01-31	2018-12-26	Tau Bio-Logic Corp.	Treatment of tauopathies
WO2012162179A1 (en) *	2011-05-20	2012-11-29	Oligomerix, Inc.	Tau protease compositions and methods of use
ES2973070T3 (es) *	2012-05-31	2024-06-18	Univ Osaka Public Corp	Agente terapéutico o agente profiláctico para la demencia
RU2668159C2 (ru)	2012-07-03	2018-09-26	Вашингтон Юниверсити	Антитела против тау
TWI734975B (zh) *	2014-06-27	2021-08-01	美商Ｃ２Ｎ醫療診斷有限責任公司	人類化抗-tau抗體
WO2017189963A1 (en) *	2016-04-29	2017-11-02	Voyager Therapeutics, Inc.	Compositions for the treatment of disease
WO2018060035A1 (en) *	2016-09-30	2018-04-05	F. Hoffmann-La Roche Ag	Spr-based dual-binding assay for the functional analysis of multispecific molecules
MX2019009817A (es)	2017-02-17	2019-11-21	Denali Therapeutics Inc	Anticuerpos anti-tau y metodos de uso de los mismos.
JP2018139530A (ja) *	2017-02-27	2018-09-13	帝人ファーマ株式会社	認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
EP3636670A4 (en)	2017-05-30	2021-06-23	Teijin Pharma Limited	ANTI-IGF-I RECEPTOR ANTIBODIES
MX2020003581A (es)	2017-10-02	2020-07-22	Merck Sharp & Dohme	Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas.
PE20210115A1 (es)	2017-10-16	2021-01-19	Eisai Randd Man Co Ltd	Anticuerpos anti-tau y uso de los mismos
JP7504026B2 (ja)	2018-04-06	2024-06-21	帝人ファーマ株式会社	Ｓｐｎｓ２中和抗体
CN112469827B (zh) *	2018-07-04	2024-05-24	学校法人爱知医科大学	控制Tau的剪接的反义寡核苷酸及其用途
CN110028583B (zh) *	2019-05-07	2020-09-11	温州医科大学	抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
JP7429404B2 (ja) *	2019-08-06	2024-02-08	慶應義塾	タウ関連疾患モデルの製造方法
JPWO2021065306A1 (es)	2019-09-30	2021-04-08
US20230137434A1 (en) *	2020-03-19	2023-05-04	Vascular Biosciences	CAR Peptide for Improved Coronavirus Survival
EP4171633A1 (en)	2020-06-25	2023-05-03	Merck Sharp & Dohme LLC	High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en)	2021-11-17	2025-01-30	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS587390B2 (ja)	1975-03-11	1983-02-09	ツキシマキカイカブシキガイシヤ	ア−クヨウセツホウホウ
JP3587390B2 (ja)	1994-03-17	2004-11-10	タカラバイオ株式会社	リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US20020086009A1 (en) *	1996-03-13	2002-07-04	Koichi Ishiguro	Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
US20080199471A1 (en) *	2002-03-01	2008-08-21	Bernett Matthew J	Optimized cd40 antibodies and methods of using the same
US8012936B2 (en)	2006-03-29	2011-09-06	New York University	Tau fragments for immunotherapy
US20070280935A1 (en) *	2006-04-07	2007-12-06	Bernd Bohrmann	Antibody that recognizes phosphorylated peptides
JP2009539406A (ja) *	2006-06-16	2009-11-19	エンビボファーマシューティカルズインコーポレイテッド	タウおよびアミロイド前駆体断片を発現する遺伝子組換えハエ
UA107571C2 (xx) *	2009-04-03	2015-01-26		Фармацевтична композиція
CN102596221B (zh) *	2009-06-10	2019-06-04	纽约大学	病理tau蛋白的免疫靶向
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2670434B1 (en) *	2011-01-31	2018-12-26	Tau Bio-Logic Corp.	Treatment of tauopathies
TR201102696U (tr) *	2011-05-27	2011-06-21	Turhal Sal�H	Bağlantısız hareketli ürün reklam standı.
ES2973070T3 (es) *	2012-05-31	2024-06-18	Univ Osaka Public Corp	Agente terapéutico o agente profiláctico para la demencia

2013
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja active Application Filing
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
2015
- 2015-11-03 HK HK15110820.8A patent/HK1210031A1/xx unknown
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
- 2019-12-17 HR HRP20192267TT patent/HRP20192267T1/hr unknown
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending

Also Published As

Publication number	Publication date
KR20150027098A (ko)	2015-03-11
AU2013268364A1 (en)	2014-12-18
SG11201407878VA (en)	2015-01-29
US20220340646A1 (en)	2022-10-27
TW202041532A (zh)	2020-11-16
EP2857039A4 (en)	2015-08-26
IL235899B (en)	2019-03-31
AR091218A1 (es)	2015-01-21
JP2016147902A (ja)	2016-08-18
JP2018111716A (ja)	2018-07-19
TWI700296B (zh)	2020-08-01
PT2857039T (pt)	2020-01-07
EP3662931B1 (en)	2023-12-06
ES2973070T3 (es)	2024-06-18
LT2857039T (lt)	2020-03-10
ME03587B (me)	2020-07-20
US20150183854A1 (en)	2015-07-02
KR20200029619A (ko)	2020-03-18
BR112014029566A2 (pt)	2017-07-25
MX361128B (es)	2018-11-28
CA2875205A1 (en)	2013-12-05
PH12014502669B1 (en)	2020-02-19
ZA201409186B (en)	2015-12-23
CN104602708B (zh)	2021-11-30
EP2857039A1 (en)	2015-04-08
PL2857039T3 (pl)	2020-05-18
PH12014502669A1 (en)	2015-02-02
CA2875205C (en)	2021-07-20
HRP20192267T1 (hr)	2020-03-20
AU2013268364B2 (en)	2018-02-08
DK2857039T3 (da)	2019-12-16
MX2014014187A (es)	2015-06-04
RS59802B1 (sr)	2020-02-28
JP6406678B2 (ja)	2018-10-17
EP3662931A1 (en)	2020-06-10
SI2857039T1 (sl)	2020-03-31
NZ630536A (en)	2017-03-31
JPWO2013180238A1 (ja)	2016-01-21
AU2018200413B2 (en)	2019-10-17
IL235899A0 (en)	2015-01-29
MY172458A (en)	2019-11-26
TW201410705A (zh)	2014-03-16
AU2018200413A1 (en)	2018-02-08
TWI777183B (zh)	2022-09-11
EP2857039B1 (en)	2019-11-20
WO2013180238A1 (ja)	2013-12-05
CY1122530T1 (el)	2021-01-27
RU2657438C2 (ru)	2018-06-13
KR102208283B1 (ko)	2021-01-26
HUE046919T2 (hu)	2020-04-28
SG10201805410XA (en)	2018-08-30
US20200148753A1 (en)	2020-05-14
ES2763361T3 (es)	2020-05-28
KR102133610B1 (ko)	2020-07-14
JP5971659B2 (ja)	2016-08-17
JP6620829B2 (ja)	2019-12-18
CN104602708A (zh)	2015-05-06
RU2014153099A (ru)	2016-07-20

Publication	Publication Date	Title
HK1210031A1 (en)	2016-04-15	Therapeutic agent or prophylactic agent for dementia
HK1211475A1 (en)	2016-05-27	Combination therapy
PL3153144T3 (pl)	2019-07-31	Urządzenie izolacyjne
SG11201501173SA (en)	2015-05-28	PI3Kδ INHIBITOR
HK1208628A1 (en)	2016-03-11	Prophylactic or therapeutic agent for hepatic diseases
HK1216297A1 (zh)	2016-11-04	腫瘤溶解綜合征的治療藥和預防藥
GB201217439D0 (en)	2012-11-14	Combination therapy
SG11201500074XA (en)	2015-03-30	Safety cabinet
HRP20181120T1 (hr)	2018-09-21	Sanitarni set
PL2554541T3 (pl)	2016-06-30	Środek terapeutyczny lub środek profilaktyczny na fibromialgię
PL399419A1 (pl)	2012-12-17	Sposób wytwarzania 4-metoksydihydrochalkonu
PL399418A1 (pl)	2012-12-17	Sposób wytwarzania 4-metoksydihydrochalkonu
IL236450A (en)	2016-08-31	Process for making 5-fluoro-h1-pyrazoles
GB201207305D0 (en)	2012-06-13	Therapy
PL2677104T3 (pl)	2018-09-28	Szafka bezpieczeństwa
HK1210426A1 (en)	2016-04-22	Combination therapy
GB2502527B (en)	2018-07-18	Plumbing apparatus
HK1212895A1 (zh)	2016-06-24	用於免疫調節的沙奎那韋-
GB201214234D0 (en)	2012-09-19	Prophylactic therapy
GB201220253D0 (en)	2012-12-26	Plumbing apparatus
PL2861904T3 (pl)	2019-01-31	Ulepszone urządzenie instalacji wodociągowej
GB201211543D0 (en)	2012-08-15	Combination therapy
PL2677099T3 (pl)	2019-05-31	Szafka bezpieczeństwa
HU229987B1 (en)	2015-04-28	Process for the preparation of pyrimidinyl-piperazines
GB201220529D0 (en)	2012-12-26	No details available